Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis.
PlGF.
Preeclampsia
sFLT-1
Angiogenic factors
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
08
11
2017
revised:
25
01
2018
accepted:
12
09
2018
entrez:
23
8
2019
pubmed:
23
8
2019
medline:
23
8
2019
Statut:
epublish
Résumé
The etiological nature of preeclampsia is heterogeneous. The use of biomarkers indices in early pregnancy helps to have appropriate stratification of pregnancies into high- and low risk for the purpose of choosing timely interventions. The aim of this systematic review was to determine the pathogenic role of soluble soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in the prediction of preeclampsia in women. We performed a systematic search of the international databases including PubMed, Scopus, and Web of Science until August 2017. The quality of included studies was assessed using the Newcastle-Ottawa Scale. The primary outcome in this review was preeclampsia. The statistical heterogeneity was assessed using the X Totally, 284 records were identified in the initial search and 15 records were finally included in the meta-analysis. The pooled odds ratios (ORs) for the association between the high level of sFlt-1 and low level of PlGF and subsequent development of preeclampsia among women were 5.20 (95% CI: 1.24-9.16) and 2.53 (95% CI: 1.33-3.75), respectively. The mean difference for sFlt-1 and PlGF in women with preeclampsia compared to controls was 1.15 (95% CI: 0.43-1.86) and -0.94 (95% CI: -1.37-0.52), respectively. According to the results from this meta-analysis, increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.
Sections du résumé
BACKGROUND
BACKGROUND
The etiological nature of preeclampsia is heterogeneous. The use of biomarkers indices in early pregnancy helps to have appropriate stratification of pregnancies into high- and low risk for the purpose of choosing timely interventions.
OBJECTIVE
OBJECTIVE
The aim of this systematic review was to determine the pathogenic role of soluble soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in the prediction of preeclampsia in women.
MATERIALS AND METHODS
METHODS
We performed a systematic search of the international databases including PubMed, Scopus, and Web of Science until August 2017. The quality of included studies was assessed using the Newcastle-Ottawa Scale. The primary outcome in this review was preeclampsia. The statistical heterogeneity was assessed using the X
RESULTS
RESULTS
Totally, 284 records were identified in the initial search and 15 records were finally included in the meta-analysis. The pooled odds ratios (ORs) for the association between the high level of sFlt-1 and low level of PlGF and subsequent development of preeclampsia among women were 5.20 (95% CI: 1.24-9.16) and 2.53 (95% CI: 1.33-3.75), respectively. The mean difference for sFlt-1 and PlGF in women with preeclampsia compared to controls was 1.15 (95% CI: 0.43-1.86) and -0.94 (95% CI: -1.37-0.52), respectively.
CONCLUSION
CONCLUSIONS
According to the results from this meta-analysis, increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.
Identifiants
pubmed: 31435580
doi: 10.18502/ijrm.v17i1.3815
pmc: PMC6652157
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
J Korean Med Sci. 2007 Oct;22(5):873-7
pubmed: 17982238
Am J Obstet Gynecol. 2010 Feb;202(2):161.e1-161.e11
pubmed: 19850276
J Clin Endocrinol Metab. 2003 May;88(5):2348-51
pubmed: 12727995
Obstet Gynecol. 2013 Nov;122(5):1122-31
pubmed: 24150027
PLoS One. 2015 May 12;10(5):e0126815
pubmed: 25965397
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Circulation. 2011 Jun 21;123(24):2856-69
pubmed: 21690502
Medicina (Kaunas). 2016;52(6):349-353
pubmed: 27940029
J Clin Endocrinol Metab. 2003 Nov;88(11):5555-63
pubmed: 14602804
Lancet. 2014 Mar 15;383(9921):970-83
pubmed: 24269108
PLoS One. 2015 Aug 28;10(8):e0136540
pubmed: 26317406
Pregnancy Hypertens. 2012 Apr 1;2(2):158-163
pubmed: 22712058
Hypertension. 2011 Dec;58(6):1120-5
pubmed: 21986503
Pregnancy Hypertens. 2014 Apr;4(2):97-104
pubmed: 26104417
Ultrasound Obstet Gynecol. 2008 Mar;31(3):303-9
pubmed: 18058842
J Clin Endocrinol Metab. 2005 Aug;90(8):4895-903
pubmed: 15886253
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
Obstet Gynecol. 2003 Jun;101(6):1266-74
pubmed: 12798535
Obstet Gynecol. 2008 Jun;111(6):1403-9
pubmed: 18515525
J Matern Fetal Neonatal Med. 2016 Nov;29(22):3670-6
pubmed: 26762770
Am J Obstet Gynecol. 2003 Jan;188(1):177-82
pubmed: 12548214
J Clin Endocrinol Metab. 2004 Feb;89(2):770-5
pubmed: 14764795
J Matern Fetal Neonatal Med. 2009 Nov;22(11):1021-38
pubmed: 19900040
Am J Obstet Gynecol. 2010 Jan;202(1):40.e1-7
pubmed: 19762001
J Clin Invest. 2003 Mar;111(5):649-58
pubmed: 12618519
Acta Obstet Gynecol Scand. 2008;87(8):837-42
pubmed: 18607829
J Matern Fetal Neonatal Med. 2008 May;21(5):279-87
pubmed: 18446652